C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · IEX Real-Time Price · USD
4.520
-0.330 (-6.80%)
At close: Jul 2, 2024, 4:00 PM
4.390
-0.130 (-2.88%)
After-hours: Jul 2, 2024, 7:30 PM EDT
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 8.71, with a low estimate of 2.00 and a high estimate of 16. The average target predicts an increase of 92.70% from the current stock price of 4.52.
Analyst Consensus: Buy
* Price targets were last updated on May 9, 2024.
Analyst Ratings
The average analyst rating for CCCC stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Hold | 3 | 3 | 3 | 3 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 7 | 7 | 7 | 8 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Wells Fargo | Wells Fargo | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +76.99% | May 9, 2024 |
Stifel | Stifel | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +209.73% | May 9, 2024 |
Morgan Stanley | Morgan Stanley | Hold Maintains $1 → $8 | Hold | Maintains | $1 → $8 | +76.99% | Feb 26, 2024 |
Stifel | Stifel | Strong Buy Reiterates $12 → $13 | Strong Buy | Reiterates | $12 → $13 | +187.61% | Feb 23, 2024 |
JP Morgan | JP Morgan | Sell → Hold Upgrades $6 | Sell → Hold | Upgrades | $6 | +32.74% | Jan 29, 2024 |
Financial Forecast
Revenue This Year
26.20M
from 20.76M
Increased by 26.24%
Revenue Next Year
17.20M
from 26.20M
Decreased by -34.34%
EPS This Year
-1.68
from -2.67
EPS Next Year
-1.86
from -1.68
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 48.3M | 31.5M | 495.5M | 4.7B | 13.5B |
Avg | 26.2M | 17.2M | 107.8M | 1.2B | 3.3B |
Low | 2.9M | n/a | n/a | n/a | 26.9M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 132.7% | 20.2% | 2,780.3% | 4,279.7% | 1,066.8% |
Avg | 26.2% | -34.3% | 526.5% | 974.5% | 187.4% |
Low | -85.8% | - | - | - | -97.7% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -1.06 | -1.42 | -0.72 |
Avg | -1.68 | -1.86 | -1.27 |
Low | -2.47 | -2.95 | -1.51 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.